$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000151655122000022 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.141M	$1.791M	$1.622M
YoY Change	-23.52%	88.75%	43.88%
% of Gross Profit
Research & Development	$1.782M	$1.427M	$1.266M
YoY Change	443.65%	62.05%	107.6%
% of Gross Profit
Depreciation & Amortization	$28.81K	$27.68K	$26.98K
YoY Change	286.19%	2640.59%	2776.12%
% of Gross Profit
Operating Expenses	$2.922M	$3.218M	$2.888M
YoY Change	60.64%	75.9%	66.24%
Operating Profit	-$2.922M	-$3.218M	-$2.888M
YoY Change	60.64%	75.9%	66.24%
Interest Expense	$211.2K	$205.3K	$199.0K
YoY Change	8.12%	8.02%	7.64%
% of Operating Profit
Other Income/Expense, Net	-$205.0K	-$195.8K	-$155.4K
YoY Change	3490.84%	1.57%	-63.29%
Pretax Income	-$3.127M	-$3.414M	-$3.043M
YoY Change	71.38%	68.81%	40.86%
Income Tax	$0.00	$5.141K
% Of Pretax Income
Net Earnings	-$3.127M	-$3.419M	-$3.043M
YoY Change	71.38%	68.93%	40.86%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.01	-$0.01
Diluted Earnings Per Share	-$0.01	-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	495.9M shares	495.9M shares	495.8M shares
Diluted Shares Outstanding	495.9M shares	495.9M shares	495.8M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$415.4K	$2.930M	$6.007M
YoY Change	-96.25%	-43.51%	16.58%
Cash & Equivalents	$415.4K	$2.930M	$6.007M
Short-Term Investments
Other Short-Term Assets	$143.9K	$113.2K	$109.8K
YoY Change	-58.2%	-59.89%	-52.11%
Inventory
Prepaid Expenses	$708.5K	$871.4K	$822.5K
Receivables	$0.00
Other Receivables
Total Short-Term Assets	$2.683M	$4.774M	$6.993M
YoY Change	-76.53%	-12.7%	29.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$86.16K	$74.93K	$80.77K
YoY Change	7.31%	381.46%	372.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.309K	$8.309K	$8.309K
YoY Change	0.0%	107.73%
Total Long-Term Assets	$185.5K	$193.5K	$218.0K
YoY Change	-26.75%	889.33%	1175.0%
TOTAL ASSETS
Total Short-Term Assets	$2.683M	$4.774M	$6.993M
Total Long-Term Assets	$185.5K	$193.5K	$218.0K
Total Assets	$2.869M	$4.967M	$7.211M
YoY Change	-75.45%	-9.49%	33.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.068M	$1.443M	$878.7K
YoY Change	548.24%	277.62%	75.8%
Accrued Expenses	$842.1K	$700.8K	$540.7K
YoY Change	84.14%	251.75%	208.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.455M	$2.290M	$2.130M
YoY Change			1957.32%
Total Short-Term Liabilities	$6.146M	$5.237M	$4.182M
YoY Change	309.28%	238.27%	202.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$8.230K	$32.42K	$55.91K
YoY Change	-91.82%
Total Long-Term Liabilities	$8.230K	$32.42K	$55.91K
YoY Change	-99.57%	-98.06%	-96.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.146M	$5.237M	$4.182M
Total Long-Term Liabilities	$8.230K	$32.42K	$55.91K
Total Liabilities	$6.154M	$5.269M	$4.238M
YoY Change	79.81%	63.8%	45.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.85M	-$53.72M	-$50.30M
YoY Change	27.05%	25.16%	23.0%
Common Stock	$53.56M	$53.42M	$53.27M
YoY Change	1.04%	18.21%	22.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.285M	-$301.8K	$2.973M
YoY Change
Total Liabilities & Shareholders Equity	$2.869M	$4.967M	$7.211M
YoY Change	-75.45%	-9.49%	33.56%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.127M	-$3.419M	-$3.043M
YoY Change	71.38%	68.93%	40.86%
Depreciation, Depletion And Amortization	$28.81K	$27.68K	$26.98K
YoY Change	286.19%	2640.59%	2776.12%
Cash From Operating Activities	-$2.057M	-$2.901M	-$2.915M
YoY Change	38.35%	73.57%	116.22%
INVESTING ACTIVITIES
Capital Expenditures	-$366.1K	-$84.04K	$1.999K
YoY Change	1273.11%	-15956.6%	-81.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$366.1K	-$84.04K	-$1.999K
YoY Change	1273.11%	-15956.6%	-81.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-91.85K	-91.85K	-$59.26K
YoY Change	-101.24%	-105.39%	-101.47%
NET CHANGE
Cash From Operating Activities	-2.057M	-2.901M	-$2.915M
Cash From Investing Activities	-366.1K	-84.04K	-$1.999K
Cash From Financing Activities	-91.85K	-91.85K	-$59.26K
Net Change In Cash	-2.515M	-3.077M	-$2.976M
YoY Change	-142.59%	-9173.93%	-210.93%
FREE CASH FLOW
Cash From Operating Activities	-$2.057M	-$2.901M	-$2.915M
Capital Expenditures	-$366.1K	-$84.04K	$1.999K
Free Cash Flow	-$1.691M	-$2.817M	-$2.917M
YoY Change	15.8%	68.49%	114.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001516551
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55136
	dei	Entity Registrant Name EntityRegistrantName	Skye Bioscience, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0692882
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11250 El Camino Real,
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	410-0266
	dei	Security12g Title Security12gTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	SKYE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	495925112	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2929895	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8983007	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4573	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4571	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	871428	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	554217	usd
CY2022Q2	us-gaap	Due From Affiliate Current DueFromAffiliateCurrent	0	usd
CY2021Q4	us-gaap	Due From Affiliate Current DueFromAffiliateCurrent	13432	usd
CY2022Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	842193	usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	113187	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	56870	usd
CY2022Q2	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	12655	usd
CY2021Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	0	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	4773931	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	9612097	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74929	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87710	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	110304	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	146972	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8309	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8309	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	2130	usd
CY2022Q2	skye	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	261647	usd
CY2022Q2	us-gaap	Assets Assets	4967473	usd
CY2021Q4	us-gaap	Assets Assets	9855088	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1443043	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	897880	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	107237	usd
CY2021Q4	skye	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	174911	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	350248	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	344450	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	122461	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2022Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	511257	usd
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	375842	usd
CY2022Q2	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	55668	usd
CY2021Q4	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	0	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	6554	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	59732	usd
CY2022Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	450000	usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	450000	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1839830	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1524905	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	88928	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	82372	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5236873	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3912222	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32422	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	78700	usd
CY2022Q2	us-gaap	Liabilities Liabilities	5269295	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3990922	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53718840	usd
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	495925112	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	495925112	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	476108445	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	476108445	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	495925	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	476108	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	52921093	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	52644221	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47256163	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-301822	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5864166	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4967473	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9855088	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1427154	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	880672	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2692807	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1490328	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1791206	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	949002	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3413575	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2076608	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	3218360	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1829674	usd
	us-gaap	Operating Expenses OperatingExpenses	6106382	usd
	us-gaap	Operating Expenses OperatingExpenses	3566936	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3218360	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1829674	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6106382	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3566936	usd
CY2022Q2	skye	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-9523	usd
CY2021Q2	skye	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	120648	usd
	skye	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-53178	usd
	skye	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	358998	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	205300	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	190058	usd
	us-gaap	Interest Expense InterestExpense	404332	usd
	us-gaap	Interest Expense InterestExpense	374963	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	117953	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	117953	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-195777	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-192753	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-351154	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-616008	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3414137	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2022427	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6457536	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4182944	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5141	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5141	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3419278	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2024027	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6462677	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4184544	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	495925112	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	378427575	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	495874560	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	357770295	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	495925112	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	378427575	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	495874560	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	357770295	shares
	us-gaap	Net Income Loss NetIncomeLoss	-6462677	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4184544	usd
	us-gaap	Depreciation Depreciation	54661	usd
	us-gaap	Depreciation Depreciation	1948	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	281722	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	258279	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	53178	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-358998	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	314925	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	287781	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	117953	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	41674	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	72427	usd
	skye	Increase Decrease In Prepaid Expenses Due From Related Parties IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties	-13432	usd
	skye	Increase Decrease In Prepaid Expenses Due From Related Parties IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties	14805	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	56317	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
	skye	Increase Decrease In Other Current Assets From Related Party IncreaseDecreaseInOtherCurrentAssetsFromRelatedParty	12655	usd
	skye	Increase Decrease In Other Current Assets From Related Party IncreaseDecreaseInOtherCurrentAssetsFromRelatedParty	0	usd
	skye	Increase Decrease In Other Assets Due From Related Parties IncreaseDecreaseInOtherAssetsDueFromRelatedParties	0	usd
	skye	Increase Decrease In Other Assets Due From Related Parties IncreaseDecreaseInOtherAssetsDueFromRelatedParties	4000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-34022	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	17799	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	105107	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-1994	usd
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	86736	usd
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	42650	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5798	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	50960	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-39722	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-33764	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	357819	usd
	skye	Increase Decrease In Other Current Liabilities Related Party IncreaseDecreaseInOtherCurrentLiabilitiesRelatedParty	55668	usd
	skye	Increase Decrease In Other Current Liabilities Related Party IncreaseDecreaseInOtherCurrentLiabilitiesRelatedParty	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5815960	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3019489	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	80830	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5212	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10170	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86042	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10170	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4783	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	153076	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-151109	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5746583	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6053110	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2716924	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8987578	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2473976	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2934468	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5190900	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2929895	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5186331	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4573	usd
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4569	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2934468	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5190900	usd
	us-gaap	Interest Paid Net InterestPaidNet	2669	usd
	us-gaap	Interest Paid Net InterestPaidNet	44087	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5141	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	761364	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	skye	Financing Of Insurance Premium FinancingOfInsurancePremium	275537	usd
	skye	Financing Of Insurance Premium FinancingOfInsurancePremium	0	usd
	skye	Accrued Financing Charges AccruedFinancingCharges	13000	usd
	skye	Accrued Financing Charges AccruedFinancingCharges	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5864166	usd
CY2022Q2	skye	Working Capital Deficit WorkingCapitalDeficit	462942	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53718840	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	150358	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3043399	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2973092	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	144364	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3419278	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-301822	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	450786	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	146580	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2160517	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	2478649	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	111699	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4783	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2024027	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2271104	usd
CY2022Q2	skye	Business Combination Consideration Transferred Equity Interests Issued And Issuable Entity Shares Issued Per Acquiree Share BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare	1.95	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2929895	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3218360	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1829674	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6106382	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3566936	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3419278	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2024027	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6462677	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4184544	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2024027	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2024027	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates and judgements as to the appropriate carrying values of equity instruments, derivative liabilities, debt with embedded features, estimates related to the Company's estimation of the percentage of completion under its research and development contracts and the valuation of stock based compensation awards, which are not readily apparent from other sources.</span></div>
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	495925112	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	495925112	shares
CY2022Q2	skye	Research And Development Licensed Technology Costs Capitalized To Date ResearchAndDevelopmentLicensedTechnologyCostsCapitalizedToDate	0	usd
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	378427575	shares
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3419278	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3419278	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6462677	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6462677	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4184544	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4184544	usd
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	378427575	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	495874560	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	495874560	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	357770295	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	357770295	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	842193	usd
	skye	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	358998	usd
	skye	Class Of Warrant Or Right Warrants Vested And Outstanding ClassOfWarrantOrRightWarrantsVestedAndOutstanding	136187225	shares
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	59732	usd
	skye	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-53178	usd
	skye	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	0	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	6554	usd
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	38567	usd
	skye	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	0	usd
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	397565	usd
CY2022Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	43608	usd
CY2021Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	43608	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	86737	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	86737	usd
CY2022Q2	skye	Insurance Premium Expense InsurancePremiumExpense	1603	usd
CY2021Q2	skye	Insurance Premium Expense InsurancePremiumExpense	159	usd
	skye	Insurance Premium Expense InsurancePremiumExpense	2669	usd
	skye	Insurance Premium Expense InsurancePremiumExpense	445	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	159645	usd
CY2021Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	145885	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	314052	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	286982	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	444	usd
CY2021Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	406	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	874	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	799	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	205300	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	190058	usd
	us-gaap	Interest Expense InterestExpense	404332	usd
	us-gaap	Interest Expense InterestExpense	374963	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	150000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	35405000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.07
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y29D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	134750	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4350000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	321250	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1678750	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.08
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	37755000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.07
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12066250	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.08
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y7D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M23D
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	144364	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	111699	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	281722	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	258279	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1381837	usd
CY2021Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2021Q3	skye	Lessee Operating Lease Abatement Term LesseeOperatingLeaseAbatementTerm	P2M
CY2021Q3	skye	Lessee Operating Lease Initial Monthly Rent LesseeOperatingLeaseInitialMonthlyRent	8067	usd
CY2021Q3	skye	Lessee Operating Lease Annual Rent Increase Percent LesseeOperatingLeaseAnnualRentIncreasePercent	0.03
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	22675	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	45350	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M29D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	48888	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	83093	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	131981	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10631	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	121350	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	88928	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32422	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	121350	usd

Files In Submission

Name	View Source	Status
0001516551-22-000022-index-headers.html	Edgar Link	pending
0001516551-22-000022-index.html	Edgar Link	pending
0001516551-22-000022.txt	Edgar Link	pending
0001516551-22-000022-xbrl.zip	Edgar Link	pending
exhibit105formofstockoptio.htm	Edgar Link	pending
exhibit106aformofstockopti.htm	Edgar Link	pending
exhibit412022commonstockwa.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skye-20220630.htm	Edgar Link	pending
skye-20220630.xsd	Edgar Link	pending
skye-20220630xex311.htm	Edgar Link	pending
skye-20220630xex312.htm	Edgar Link	pending
skye-20220630xex321.htm	Edgar Link	pending
skye-20220630xex322.htm	Edgar Link	pending
skye-20220630_def.xml	Edgar Link	unprocessable
skye-20220630_pre.xml	Edgar Link	unprocessable
skye-20220630_lab.xml	Edgar Link	unprocessable
skye-20220630_htm.xml	Edgar Link	completed
skye-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2022 Q3 Form 10-Q Financial Statement

#000151655122000022 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2022 Q3 Form 10-Q Financial Statement

#000151655122000022 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye